摘要
目的分析浸润性导管癌合并导管原位癌(IDC+DCIS)与单纯浸润性导管癌(IDC)的临床病理特点。方法 2016~2020年我科收治的乳腺癌病人335例,其中IDC+DCIS组123例,IDC组212例。采用SPSS 23.0软件进行统计分析,比较两组间肿块大小,淋巴结分期以及雌激素受体、孕激素受体、人类表皮生长因子受体2(HER-2)、细胞增殖核抗原、细胞角蛋白5/6(CK5/6)等分子指标的表达差异。结果 IDC+DCIS组的HER-2阳性率明显高于IDC组(40.7%vs 25%,P=0.003),而CK5/6的阳性率显著低于IDC组(10.4%vs 42.6%,P=0.00)。此外IDC组有更高的三阴型乳腺癌比率(23.3%vs 9.8%,P=0.02)。结论 IDC+DCIS与IDC比较,表现出不同的免疫组化表型。这种表型的差异是否预示着两种癌通过不同的途径浸润,值得进一步探讨。
Objective Analyze the clinicopathological features of invasive ductal carcinoma with ductal carcinoma in situ(IDC+DCIS) and invasive ductal carcinoma(IDC).Methods 335 breast cancer patients treated in the Department of Thyroid and Breast Surgery, Maternal and Child Hospital of Hubei Province from 2016 to 2020 were adopted, including 123 patients in the IDC+DCI group and 212 patients in the IDC group.SPSS 23.0 software was used for statistical analysis to compare the tumor size, lymph node stage, and the expression of ER,PR,HER-2,Ki-67%,CK5/6 and other molecular indicators between the two groups.Results The expression of HER-2 in the IDC+DCIS group was higher than that in the IDC group(40.7% vs 25%,P=0.003),while the positive rate of CK5/6 was significantly lower than that in the IDC group(10.4% vs 42.6%,P=0.00).In addition, the IDC group had a higher rate of triple negative breast cancer(23.3% vs 9.8%,P=0.02).Conclusion Compared with invasive carcinoma, invasive ductal carcinoma with carcinoma in situ shows different immunohistochemical phenotype.Whether this difference in phenotype indicates that the two cancers infiltrate through different pathways is worthy of further research.
作者
郑媛
陈波
ZHENG Yuan;CHEN Bo(Department of Throid and Breast Surgery,Maternal and Child Health Hospital of Hubei Province,Wuhan 430070,China)
出处
《临床外科杂志》
2021年第11期1047-1049,共3页
Journal of Clinical Surgery
关键词
乳腺肿瘤
原位乳腺癌
免疫组织化学
breast neoplasms
breast carcinoma in situ
immunohistochemistry
